Neutralization of biotin interference : preliminary evaluation of the VeraTest Biotin™, VeraPrep Biotin™ and BioT-Filter®
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 58(2020), 8 vom: 28. Juli, Seite e130-e133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Favresse, Julien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6SO6U10H04 |
|---|
| Anmerkungen: |
Date Completed 17.08.2021 Date Revised 17.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2019-1121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30684642X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30684642X | ||
| 003 | DE-627 | ||
| 005 | 20231225124253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2019-1121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM30684642X | ||
| 035 | |a (NLM)32092039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Favresse, Julien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralization of biotin interference |b preliminary evaluation of the VeraTest Biotin™, VeraPrep Biotin™ and BioT-Filter® |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2021 | ||
| 500 | |a Date Revised 17.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a biotin | |
| 650 | 4 | |a immunoassay | |
| 650 | 4 | |a interference | |
| 650 | 4 | |a patient safety | |
| 650 | 4 | |a streptavidin | |
| 650 | 7 | |a Biotin |2 NLM | |
| 650 | 7 | |a 6SO6U10H04 |2 NLM | |
| 650 | 7 | |a Streptavidin |2 NLM | |
| 650 | 7 | |a 9013-20-1 |2 NLM | |
| 700 | 1 | |a Bayart, Jean-Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Stoefs, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Gheldof, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Gruson, Damien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 58(2020), 8 vom: 28. Juli, Seite e130-e133 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:8 |g day:28 |g month:07 |g pages:e130-e133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2019-1121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 8 |b 28 |c 07 |h e130-e133 | ||